Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
Maël Heiblig(Hospices Civils de Lyon), Pierre Sujobert(Hospices Civils de Lyon)
Cited by 201
Related Papers
No related papers found
Powered by citation graph analysis